Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Cancer Discovery - Tập 4 Số 9 - Trang 998-1013 - 2014
Manuel Hidalgo1, Frédéric Amant2, Andrew V. Biankin3, Eva Budínská4, Annette T. Byrne5, Carlos Caldas6, Robert B. Clarke7, Steven de Jong8, Jos Jonkers9, Gunhild M. Mælandsmo10, Sergio Roman‐Roman11, Joan Seoane12, Livio Trusolino13,14, Alberto Villanueva15
11Centro Nacional de Investigaciones Oncológicas, Madrid;
24Katholieke Universiteit Leuven, Leuven, Belgium;
35Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow;
48Masaryk University, Brno, Czech Republic;
59Royal College of Surgeons in Ireland, Dublin, Ireland;
66Cambridge Cancer Centre, Cambridge;
77Breakthrough Breast Cancer Unit, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom;
810Department of Medical Oncology, University of Groningen, University Medical Centre Groningen, Groningen;
911The Netherlands Cancer Institute, Amsterdam, the Netherlands;
1012Oslo University Hospital, Oslo, Norway;
1113Institut Curie, Paris, France;
122Vall d'Hebron Institute of Oncology;
1314Candiolo Cancer Institute – FPO IRCCS; and
1415Department of Oncology, University of Torino, Candiolo, Torino, Italy
153Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain;

Tóm tắt

Abstract Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models. Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. Cancer Discov; 4(9); 998–1013. ©2014 AACR.

Từ khóa


Tài liệu tham khảo

Boyd, 1997, The NCI in vitro antitumor drug discovery screen: concept, implementation, and operation, 1985–1995.

Venditti, 1984, Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976–1982, and future directions., Adv Pharmacol Chemother, 20, 1, 10.1016/S1054-3589(08)60263-X

Abaan, 2013, The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology., Cancer Res, 73, 4372, 10.1158/0008-5472.CAN-12-3342

Johnson, 2001, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials., Br J Cancer, 84, 1424, 10.1054/bjoc.2001.1796

Gillet, 2011, Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance., Proc Natl Acad Sci U S A, 108, 18708, 10.1073/pnas.1111840108

Hausser, 2005, Phenotypic instability of Saos-2 cells in long-term culture., Biochem Biophys Res Commun, 333, 216, 10.1016/j.bbrc.2005.05.097

Fiebig, 1985, Development of three human small cell lung cancer models in nude mice., Recent Results Cancer Res, 97, 77, 10.1007/978-3-642-82372-5_8

Houghton, 1982, Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice., Cancer Res, 42, 535

Berger, 1990, Preclinical phase II study of ifosfamide in human tumour xenografts in vivo., Cancer Chemother Pharmacol, 26, S7, 10.1007/BF00685408

Calles, 2013, Primary human non–small cell lung and pancreatic tumorgraft models—utility and applications in drug discovery and tumor biology., Curr Protoc Pharmacol, 10.1002/0471141755.ph1426s61

Siolas, 2013, Patient-derived tumor xenografts: transforming clinical samples into mouse models., Cancer Res, 73, 5315, 10.1158/0008-5472.CAN-13-1069

Tentler, 2012, Patient-derived tumour xenografts as models for oncology drug development., Nat Rev Clin Oncol, 9, 338, 10.1038/nrclinonc.2012.61

Kim, 2009, Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice., Nat Protoc, 4, 1670, 10.1038/nprot.2009.171

Nemati, 2010, Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors., Clin Cancer Res, 16, 2352, 10.1158/1078-0432.CCR-09-3066

Sivanand, 2012, A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma., Sci Transl Med, 4, 137ra75, 10.1126/scitranslmed.3003643

Zhang, 2013, A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models., Cancer Res, 73, 4885, 10.1158/0008-5472.CAN-12-4081

Ginestier, 2007, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome., Cell Stem Cell, 1, 555, 10.1016/j.stem.2007.08.014

Vidal, 2012, Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer., Clin Cancer Res, 18, 5399, 10.1158/1078-0432.CCR-12-1513

Wang, 1992, A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice., Int J Cancer, 51, 992, 10.1002/ijc.2910510626

Dong, 2010, Patient-derived first generation xenografts of non–small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy., Clin Cancer Res, 16, 1442, 10.1158/1078-0432.CCR-09-2878

Fichtner, 2008, Establishment of patient-derived non–small cell lung cancer xenografts as models for the identification of predictive biomarkers., Clin Cancer Res, 14, 6456, 10.1158/1078-0432.CCR-08-0138

Li, 2013, Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts., Cell Rep, 4, 1116, 10.1016/j.celrep.2013.08.022

Kresse, 2012, Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations., Cancer, 118, 558, 10.1002/cncr.26276

Ding, 2010, Genome remodelling in a basal-like breast cancer metastasis and xenograft., Nature, 464, 999, 10.1038/nature08989

Keysar, 2013, A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins., Mol Oncol, 7, 776, 10.1016/j.molonc.2013.03.004

Rubio-Viqueira, 2006, An in vivo platform for translational drug development in pancreatic cancer., Clin Cancer Res, 12, 4652, 10.1158/1078-0432.CCR-06-0113

Daniel, 2009, A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro., Cancer Res, 69, 3364, 10.1158/0008-5472.CAN-08-4210

Bertotti, 2011, A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer., Cancer Discov, 1, 508, 10.1158/2159-8290.CD-11-0109

Julien, 2012, Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer., Clin Cancer Res, 18, 5314, 10.1158/1078-0432.CCR-12-0372

DeRose, 2011, Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes., Nat Med, 17, 1514, 10.1038/nm.2454

Reyal, 2012, Molecular profiling of patient-derived breast cancer xenografts., Breast Cancer Res, 14, R11, 10.1186/bcr3095

Moestue, 2010, Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models., BMC Cancer, 10, 433, 10.1186/1471-2407-10-433

Garrido-Laguna, 2011, Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer., Clin Cancer Res, 17, 5793, 10.1158/1078-0432.CCR-11-0341

Marangoni, 2007, A new model of patient tumor-derived breast cancer xenografts for preclinical assays., Clin Cancer Res, 13, 3989, 10.1158/1078-0432.CCR-07-0078

Hidalgo, 2011, A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer., Mol Cancer Ther, 10, 1311, 10.1158/1535-7163.MCT-11-0233

Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat Rev Drug Discov, 3, 711, 10.1038/nrd1470

Migliardi, 2012, Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas., Clin Cancer Res, 18, 2515, 10.1158/1078-0432.CCR-11-2683

Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine., N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369

Garrido-Laguna, 2010, Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer., Br J Cancer, 103, 649, 10.1038/sj.bjc.6605819

Rajeshkumar, 2009, Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer., Clin Cancer Res, 15, 4138, 10.1158/1078-0432.CCR-08-3021

Sebastiani, 2006, Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival., Clin Cancer Res, 12, 2492, 10.1158/1078-0432.CCR-05-2655

Moestue, 2011, HR MAS MR spectroscopy in metabolic characterization of cancer., Curr Top Med Chem, 11, 2, 10.2174/156802611793611869

Moestue, 2013, Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts., J Magn Reson Imaging, 38, 1043, 10.1002/jmri.24079

Bardelli, 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov, 3, 658, 10.1158/2159-8290.CD-12-0558

Das Thakur, 2013, Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance., Nature, 494, 251, 10.1038/nature11814

Anido, 2010, TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma., Cancer Cell, 18, 655, 10.1016/j.ccr.2010.10.023

Lonardo, 2011, Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy., Cell Stem Cell, 9, 433, 10.1016/j.stem.2011.10.001

Mueller, 2009, Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer., Gastroenterology, 137, 1102, 10.1053/j.gastro.2009.05.053

Yen, 2012, Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells., Clin Cancer Res, 18, 5374, 10.1158/1078-0432.CCR-12-0736

Junttila, 2013, Influence of tumour micro-environment heterogeneity on therapeutic response., Nature, 501, 346, 10.1038/nature12626

Chen, 2012, A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response., Nature, 483, 613, 10.1038/nature10937

Nardella, 2011, The APL paradigm and the “co-clinical trial” project., Cancer Discov, 1, 108, 10.1158/2159-8290.CD-11-0061

Jimeno, 2006, Assessment of celecoxib pharmacodynamics in pancreatic cancer., Mol Cancer Ther, 5, 3240, 10.1158/1535-7163.MCT-06-0565

Dancey, 2012, The genetic basis for cancer treatment decisions., Cell, 148, 409, 10.1016/j.cell.2012.01.014

Garraway, 2013, Genomics-driven oncology: framework for an emerging paradigm., J Clin Oncol, 31, 1806, 10.1200/JCO.2012.46.8934

Diaz, 2012, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers., Nature, 486, 537, 10.1038/nature11219

Garber, 2007, Personal mouse colonies give hope for pancreatic cancer patients., J Natl Cancer Inst, 99, 105, 10.1093/jnci/djk046

Valencia, 2012, Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics., Genome Med, 4, 61, 10.1186/gm362

Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity., Nature, 483, 603, 10.1038/nature11003

De Wever, 2003, Role of tissue stroma in cancer cell invasion., J Pathol, 200, 429, 10.1002/path.1398

Kleine, 1986, Prognostic significance of growth characteristics of xenotransplanted ovarian carcinomas into nude mice., Gynecol Oncol, 25, 65, 10.1016/0090-8258(86)90066-1

Kondo, 2011, Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer., Proc Natl Acad Sci U S A, 108, 6235, 10.1073/pnas.1015938108

Weiswald, 2009, Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness., Br J Cancer, 101, 473, 10.1038/sj.bjc.6605173

Dalerba, 2011, Single-cell dissection of transcriptional heterogeneity in human colon tumors., Nat Biotechnol, 29, 1120, 10.1038/nbt.2038

Kamiyama, 2013, Personalized chemotherapy profiling using cancer cell lines from selectable mice., Clin Cancer Res, 19, 1139, 10.1158/1078-0432.CCR-12-2127

Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing., N Engl J Med, 366, 883, 10.1056/NEJMoa1113205

Shah, 2012, The clonal and mutational evolution spectrum of primary triple-negative breast cancers., Nature, 486, 395, 10.1038/nature10933

Yachida, 2010, Distant metastasis occurs late during the genetic evolution of pancreatic cancer., Nature, 467, 1114, 10.1038/nature09515

Baccelli, 2013, Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay., Nat Biotechnol, 31, 539, 10.1038/nbt.2576

Embuscado, 2005, Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy., Cancer Biol Ther, 4, 548, 10.4161/cbt.4.5.1663

Kalscheuer, 2012, A model for personalized in vivo analysis of human immune responsiveness., Sci Transl Med, 4, 125ra30, 10.1126/scitranslmed.3003481

van der Meel, 2010, Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies., Drug Discov Today, 15, 102, 10.1016/j.drudis.2009.12.003

O'Neill, 2010, Bioluminescent imaging: a critical tool in pre-clinical oncology research., J Pathol, 220, 317, 10.1002/path.2656

Welm, 2008, Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer., Cell Stem Cell, 2, 90, 10.1016/j.stem.2007.10.002

Yuan, 2012, Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling., Sci Transl Med, 4, 157ra43, 10.1126/scitranslmed.3004330

Aytes, 2012, Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype., Mol Carcinog, 51, 746, 10.1002/mc.20843

Reyes, 1996, Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice., Cancer Res, 56, 5713

Kimple, 2013, Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts., Clin Cancer Res, 19, 855, 10.1158/1078-0432.CCR-12-2746

Thông tin
Thông tin xuất bản

Cancer Discovery

Tập 4 Số 9

998-1013

Thông tin tác giả